Member Info for draft

I will now be monitoring this bb more closely. If Tobriand is TB, then quite frankly he should not be posting here at all. And certainly the posts are very much against FBDU also because Stone Checker uses TEXRAD so quite barmy to be ****ging off both companies. i will be keeping an eye on this.

Botak and Elartu, what was the last date TB popped up and ****ged off feedback? and on avdfn or on here?

Can you give me the user ID please?

EHSC cyber company is up 20% today, thats concerning - why isnt this going up then.

Elartu - I am not aware that what you are saying has ever happened? Mayeb you take that up directly with ceo?

FBDU did explain on interview they were working closely with FDA and decided to revise the application to compare against a device more familiar to the FDA. A lot of info regarding FDA timeline is explained in todays rns

im already up 100% on this, i bought more around 0.55 - 0.60

Job done

Feedback PLC (FDBK) TexRAD� ordered by Samsung Medical Centre in Seoul

we haev ISG Korea also and Stonechecker uses Texrad.

you really have been quite annoying to be honest. youve constantly been panicking, ENJOY this suspension,

Well on track. Revenue was £126,000 - thats 50% ahead of where Imaging Biometrics usually is. IB was £165,000 for 12 months revenue last time, now in just 6 months its done £126,000! Thats £252,000 for 12 months and we know IB is predicted to go up to ££500,000 a year in 2019 ($250,000 per quarter recurring as in prospectus)

http://newsroom.gehealthcare.com/image-brain-radiologists-researchers-waiting-rsna/?utm_source=twitter.com&utm_medium=GESocial&utm_content=Signa+Premier+radiologists&utm_campaign=RSNA17

Testimonials

Our products and services certainly speak for themselves, however sometimes, testimonials from our customers can go a long way. Below are just a few of our recent satisfied customers.
Dr. Jennifer Connelly, MD, Associate Professor of Neurology
Froedtert Health and Medical College of Wisconsin

Take a look at the MRIs from yesterday compared to the prior one. The T1 with contrast is hard to interpret but I think the [standardized] Delta T1 says it all.
Jamie Beaudry, Director of Imaging Services
Froedtert and the Medical College of Wisconsin

We've been working with Imaging Biometrics for more than a year and have found the organization to be extremely organized and responsive. They are very collaborative in working with the leadership and staff who've been involved with our MR-focused initiative to improve patient scheduling and reception and to stream-line processes to improve patient satisfaction and department efficiency.

They've definitely put in the time and effort to get to know our department, staff, and workflows to better understand the challenges we face. I appreciate how they continuously check in to make sure we are moving in the right direction and getting the outcomes we expect.

Froedtert & the Medical College of Wisconsin has used LEAN principles for many years for numerous process improvement initiatives across our hospital and health system. We are pleased that Imaging Biometrics is supporting us in this specific endeavor in our Imaging Services department.

Froedtert & the Medical College of Wisconsin Hospital is a 500-bed academic medical center and a leading referral resource for advanced medical care. Froedtert Hospital also operates the region's only adult Level 1 Trauma Center. The primary adult teaching affiliate of the Medical College of Wisconsin, Froedtert Hospital is a major training facility for more than 1,000 medical, nursing, and health technical students annually. It is also a respected research center, participating in some 2,000 research studies, including clinical trials, every year. Froedtert Hospital is located on the Milwaukee Regional Medical Center campus. Campus partners are: BloodCenter of Wisconsin, Children's Hospital of Wisconsin, Curative Care Network, the Medical College of Wisconsin, and the Milwaukee County Behavioral Health Division. For more information, visit froedtert.com.

An interactive virtual reality solution, EchoPixel uses existing DICOM image data to allow clinicians to create and interact with life-size holographic objects of patient anatomy for diagnostics, surgical planning and interventional radiology.

Investments aim at interoperability, value-based care

Rounding out our activity, two strategic buyers -- Konica Minolta through its acquisition of Invicro and ERT Clinical with its acquisition of Cleveland Clinic's Biomedical Imaging and Analysis Center -- acquired clinical trial imaging capabilities. These acquisitions offer a clear reminder of the increasing importance of imaging in drug discovery.

In addition, LifeImage, a medical information network connecting other healthcare networks, providers and patients to imaging records, raised an additional $6.5 million last April; the growing emphasis on industry interoperability makes this transaction stand out. Value-based healthcare marches on, if at a slower-than-hoped-for pace, and Philips' acquisition of Analytics Informatics and its performance improvement solution in November 2017 highlights the continued emphasis on quality and performance.

AI was the star of the medical imaging market in my research, with workflow and post-processing remaining key overarching topics. There was some highlighting of innovative technologies and a reminder about the importance of imaging for clinical trials, along with brief cues about interoperability and the need for quality and performance. All in all, a year of robust transactions in the medical imaging market.

They have various foci and levels of capability in single versus multiple clinical areas, single versus multimodality and differing emphasis on radiologist workflow. For example, Ultromics focuses on improving cardiovascular disease diagnostics specifically using echocardiograms, while Zebra Medical's capabilities include liver, lung, cardiovascular and bone disease. In addition to its diagnostic capabilities, AIDoc Medical provides radiologist workflow enhancement by previewing the clinical data for the radiologist that's most relevant for interpretation.

All that said, we likely have a few more years before AI-enhanced imaging tools become mainstream. KLAS Research published a report in February 2018 called "Artificial Intelligence in Imaging 2018: Early Adopters Speak Out." In the report, KLAS spoke with 81 healthcare organizations -- primarily large, integrated delivery networks -- about each organization's early use of and plans for AI in imaging. Perhaps not surprising to many industry observers, 53% of respondents had no current plans to use AI in imaging, and only 17% of respondents were live or piloting AI. Of the 30% of respondents that were planning to use AI, only 21% expected to go live in less than a year, while 41% had go-live plans for the next year or two and 15% expected adoption to take five-plus years.
Emerging technologies

Venture investors interested in diagnostic imaging typically look for emerging technologies, and while they accounted for only 12% of the medical imaging market transactions, the three emerging tech companies funded within the period I researched all use imaging technologies in new and creative ways:

Analytics 4 Life wants to enhance cardiac imaging and the assessment of coronary artery diseases. The company takes intrinsic signals emitted by the heart and, with AI, measures and mathematically models those signals using phase space tomography -- a field of math and physics that models dynamic systems and allows the company's imaging process to be completed without radiation, contrast agents or cardiac stress.
Ortho Kinematics created a new diagnostic tool for the assessment of spinal instability and alignment, which was historically measured by hand from static x-rays. The tool, called Vertebral Motion Analysis (VMA), uses fluoroscopic imaging during controlled patient movement -- while VMA devices assist patients through the motion of a spine bend -- combined with additional image processing and motion analysis. With this new technology, Ortho Kinematics claims the ability to increase sensitivity in detecting lumbar radiographic instability by 500%.
An interactive virtual reality solution, EchoPixel uses existing DICOM image data to allow clinicians to create and interact with life-size holographic objects of patient anatomy for diagnostics, surgical planning and interventional radiology.

Investments aim at interoperability, value-based care

Rounding out our activity, two stra

Investors in medical imaging technology leaned toward software that improves AI-related radiology and associated workflows, as evidenced by detailed research. o find out the types of diagnostic imaging software that companies have been gaining favor with and see what medical imaging market trends the data revealed, I investigated strategic acquisitions in medical imaging as well as areas attracting investments.

With nine acquisitions and close to a quarter-billion dollars in investments, the 16 months from March 2017 through June 2018 were busy for the medical imaging space. My research also revealed the following:

AI-enabled medical image analysis emerged as the big winner, with nine companies raising a combined $130 million in investments.
With $52 million spread among three investments, other emerging technologies were silver medalists.
Next up was a single $16-million investment and two additional acquisitions in image post-processing without the use of AI as well as a single $30-million investment in workflow tools -- a category that also saw two acquisitions.
Imaging for clinical trials was also noteworthy, with two vendors acquired by strategic buyers.
Finally, there were companies that don't necessarily fit into any of the above categories: Two investments received a combined $13 million in funding, and three other companies were acquired.

Improved radiologist workflow capabilities

During the 16-month period I researched, investments and acquisitions in the imaging space overwhelmingly focused on improving post-processing and workflow for radiologists using traditional and AI-enabled methods; 15 of the 25 transactions fall into this category. Simply, this trend speaks to improving radiologist diagnostic capability and speed with enhanced and, in some cases, intelligent post-processing capabilities and workflow. Since radiologists clearly offer an expensive and limited resource, improving their efficacy and efficiency has been a key goal for the last few years -- although for medical imaging market transactions in this category, 60% was higher than I expected.
AI-enabled medical image analysis

Imaging is a key area in which AI has the potential for significant near- to mid-term impact, so I anticipated that investors would seek out related opportunities, which we've obviously seen in this data. The nine companies that received investments -- AIDoc Medical, Zebra Medical Vision, Ultromics, Bay Labs, Imagen, VoxelCloud, Brainomix, Huiyi Hui Ying and 12 Sigma Technologies -- have all embraced AI to assist in identifying abnormalities and assorted other clinical findings in medical images.

Since radiologists clearly offer an expensive and limited resource, improving their efficacy and efficiency has been a key goal for the last few years.

They have various foci and levels of capability in single versus multiple clinical areas, single versus multimodality and differing emphasis on radiologist wo

https://searchhealthit.techtarget.com/opinion/In-the-medical-imaging-market-AI-drives-investment-dollars

actually their holding was diluted by the placing. West Coast Capital Investments 7,559,934 6.28%

In March 2001, Hunter was a founding partner of West Coast Capital, the private equity arm of the Hunter Family. Through this firm, he has become a major shareholder in a number of retailers – including USC, Office, D2, Qube; and 8% of British Home Stores (BHS), with the bulk owned by Sir Philip Green, subsequently disposing of them all. His other investments included Wyevale Garden Centres.[2][4]

At its height, West Coast investments covered over 50 companies, and Hunter was touted as a possible bidder for Selfridges – he lost out to Galen Weston.[8] However, in light of the Financial crisis of 2007–2008 he sold his stake in Dobbies Garden Centres to partner Tesco, lost his entire holding in Crest Nicholson; and a majority of his stakes in McCarthy & Stone and Wyevale Garden Centres.[9]

West Coast Capital now holds a number of major investments in property, ecommerce and data analytics including a large stake in listed Secure Income Reit Plc, majority control of the £1 billion Winchburgh Village development and a substantial stake in Order Dynamics. West Coast Capital directly funds, alongside the Hunter Family, venture philanthropy, The Hunter Foundation.

Wonder if Dr Qu Li and Vinod have got shares yet - they must be in the placing probably.

West Coast invesments owns 10.45% - West Coast is a company of Tom Hunters. Sir Thomas Blane Hunter (born 6 May 1961) is a Scottish businessman,[1] entrepreneur, and philanthropist.

In April 2007, Hunter was reported in the Sunday Times Rich List as the first ever home-grown billionaire in Scotland, with an estimated wealth of £1.05 billion.[2] Due to the financial crisis of 2007–2010 slicing an estimated £250 million from his fortune, Hunter was overtaken as Scotland's richest man in late 2007 by Jim McColl, head of Glasgow engineering firm Clyde Blowers, who has an estimated fortune of £800 million.[3]

Kirkstall recently signed a worldwide marketing and distribution agreement with a leading Swiss life-science company, Lonza – a group which had sales of £2.6 billion in 2017.

The Japanese drinks giants follow in the footsteps of many large companies, including General Mills, Yakult Honsha, House Foods, Riken Vitamin, Kikkoman, Barilla, Ito En, The Coca-Cola Company, Lipton, POM Wonderful LLC, Welch's, Ocean Spray, who have worked with PETA to ban unnecessary animal testing. In this instance, PETA has yet again gone above and beyond and helped push some of Japan’s largest drinks and food companies into changing their policies. A great day for animal lovers and consumers alike, who can rest easy knowing that their favourite brands are doing what they can to enforce animal rights.